ReGene53

Home

Welcome to ReGene53™

ReGene53 is a next-generation therapeutic platform targeting TP53 dysfunction, the most commonly altered pathway in cancer. Our mission is to restore functional tumor suppression by selectively modulating TP53 isoforms and stabilizing the TP53–MDM2 interaction, addressing a critical unmet need across solid tumors and hematologic malignancies.

🎯 Our Approach

At the heart of ReGene53 lies a dual-strategy therapeutic innovation:

  1. Isoform-Targeted Modulation
    We are developing proprietary small molecules and gene-editing tools designed to restore the function of delta40p53 and p53β isoforms, which are frequently dysregulated in aggressive cancers.
  2. MDM2–TP53 Complex Rebalancing
    By disrupting aberrant MDM2–TP53 binding, our molecules aim to rescue wild-type TP53 activity without triggering the off-target toxicity associated with classical MDM2 inhibitors.

🧪 Scientific Platform

ReGene53 integrates:
– High-resolution structure-guided design
– Isoform-specific docking and molecular dynamics simulations
– MM/GBSA binding free energy profiling
– CRISPRi and LNP delivery systems (PEG-free validated)

We leverage in silico discovery to streamline in vitro and in vivo translation—ensuring rapid iteration with precision.

📊 Latest Progress

– Lead Compounds Identified
Our two lead candidates (“Compound A” for delta40p53α, and “Compound B” for p53β) have shown strong binding in simulated and cellular MDM2–TP53 co-immunoprecipitation assays.

– PEG-Free LNP Delivery System
We’ve finalized a proprietary lipid nanoparticle formulation compatible with TP53-targeted RNA therapeutics, eliminating PEG-associated risks.

– CRISPR Off-Target Clearance
All guide RNAs used in our delivery programs have undergone comprehensive off-target profiling via CRISPResso2 and Cas-OFFinder pipelines.

🤝 Collaborate With Us

We are actively seeking research partnerships and funding collaborations to accelerate IND-enabling studies. If you’re a pharmaceutical innovator, academic partner, or investment body interested in restoring tumor suppression in TP53-driven cancers, we invite you to connect.

No therapeutic compounds mentioned are approved for clinical use. All preclinical and in silico data are part of an ongoing research program.